Extending the dosing interval of Rituximab to 12 months did not increase the risk of disease activity in relapsing multiple sclerosis compared to 6-month dosing.
Does extending the rituximab dosing interval to 12 months increase the risk of disease activity compared with continuing every 6 months dosing in persons with relapsing multiple sclerosis?
In patients with relapsing multiple sclerosis stable on rituximab, extending the dosing interval from 6 to 12 months does not appear to increase the risk of disease activity.
Absolute Event Rate: 0% vs 0%
This study provides Class IV evidence that in persons with RMS with NEDA-3 in the 12 months following RTX, extending the dosing interval to 12 months did not increase the risk of disease activity compared with continuing q6mo dosing.
Langer-Gould et al. (Mon,) reported a other. Extending the dosing interval of Rituximab to 12 months did not increase the risk of disease activity in relapsing multiple sclerosis compared to 6-month dosing.